ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PBYI vs NGNE // DIVIDEND YIELD & FCF PAYOUT SAFETY

Puma Biotechnology Inc (NASDAQ) VS. Neurogene Inc. (NASDAQ) • 15-METRIC TALLY: PBYI 4 — NGNE 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBYI VS. NGNE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PBYI NGNE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 74.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 29.30% -35.00% +64.30 PBYI /roic <GO>
EV/EBITDA & P/E Valuation 13.8x — — TIE /valuation <GO>
Free Cash Flow Yield 7.67% -13.59% +21.26 PBYI /fcf-yield <GO>
Operating Margin 16.30% — — TIE /operating-margins <GO>
Net Profit Margin 13.60% — — TIE /net-margins <GO>
Revenue Growth (YoY) -0.90% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 12.76 -12.56 NGNE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 PBYI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.6 50.6 +2.00 PBYI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 16.3x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $538.9M $551.3M -$12.4M NGNE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PBYI REV NGNE REV PBYI GROSS % NGNE GROSS % PBYI FCF NGNE FCF
FY 2025 $228.4M $289.3M 74.5% — $41.7M -$78.4M
FY 2024 $230.5M $925.0K 72.1% — $38.9M -$71.4M
FY 2023 $235.6M $155.6M — — $27.0M -$51.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBYI // BETA —
NGNE // BETA —